A Prospective Open-Label Single-Arm Phase II Study of Chimeric Monoclonal Antibody cG250 in Advanced Renal Cell Carcinoma Patients Cited by

Fol. Biol. 2003, 49, 74-77

https://doi.org/10.14712/fb2003049020074

A Prospective Open-Label Single-Arm Phase II Study of Chimeric Monoclonal Antibody cG250 in Advanced Renal Cell Carcinoma Patients

Zoltan Varga¹, P. De Mulder², W. Kruit³, A. Hegele¹, R. Hofmann¹, C. Lamers³, S. Warnaar⁴, C. Mala⁴, S. Ullrich⁴, P. Mulders²

¹Department of Urology, Philipps-University Marburg, Germany
²University Medical Center Nijmegen, The Netherlands
³Rotterdam Cancer Institute & Academic Hospital, The Netherlands
⁴Wilex AG Munich, Germany

Received January 2003
Accepted February 2003

Crossref Cited-by Linking

Curtis Kelly K., Wong William W., Ross Helen J.: Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. Critical Reviews in Oncology/Hematology 2016, 103, 86. <https://doi.org/10.1016/j.critrevonc.2016.05.005>